" class="no-js "lang="en-US"> Exscientia Archives - Pharmtech Focus
Tuesday, January 31, 2023

Sort by:

Date

Top Post

ProPharma Acquires UK Based Digital Lab Consulting

ProPharma Group (ProPharma) the leading global provider of regulatory, clinical, and quality services for the […]

Exscientia Builds Automated Laboratories in Oxford to Expand Pipeline

Exscientia today announced the opening of a 21,000 square foot expansion of its facilities at […]

Exscientia Accelerates COVID-19 Drug Discovery Using AI

Exscientia has received a grant from the Bill & Melinda Gates Foundation and Gates Philanthropy […]

EQRx and Exscientia Enter Strategic Drug Creation, Development, and Commercialization Collaboration to Accelerate the Advancement of New World-Class Medicines

EQRx, a company committed to developing and delivering important new medicines to patients at radically […]

Exscientia Announces Second Molecule Created Using AI from Sumitomo Dainippon Pharma Collaboration to Enter Phase 1 Clinical Trial

Exscientia Ltd. (Headquarters: Oxford, UK; CEO: Andrew Hopkins) is pleased to acknowledge that Sumitomo Dainippon Pharma Co., […]

Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials

Exscientia, a leading artificial intelligence (AI)-driven pharmatech company, today announced the first AI-designed molecule for […]

  1. MedRhythms Feasibility Study Shows Positive Topline Results in Parkinson’s Disease Read more
  2. Ionis receives FDA Fast Track designation for Olezarsen in patients with Familial Chylomicronemia Syndrome Read more
  3. Sensorion and EVEON Collaborating to Develop an Injection System for the Delivery of Gene Therapy Treatments Into the Inner Ear Read more
  4. Qurient Announces Dosing of First Patient in Clinical Study for the Treatment of Patients with Solid Tumors Read more
  5. Marinus Pharmaceuticals Appoints Christine Silverstein to its Board of Directors Read more